Navigation Links
Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
Date:9/11/2009

p> Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $17bn in 2008.[1]

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by Novexel's partner, Forest Laboratories (NYSE: FRX), solely for North American markets.

Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel has a team of 50 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA.

    [1] Source: IMS Health, MIDAS, 2006-2008

    For further information please contact:

    Novexel
    Gordon Waldron, CFO
    Tel: +33-1-5714-0
'/>"/>
SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush
2. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
3. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
4. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
5. iSEEK Enterprise Presents Collaboration with Penn Medicine at 2009 AMEE Conference
6. Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium
7. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
9. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
10. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
11. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Theravalues Corporation est fier d,annoncer ... européen au salon Hi Europe 2014 (du 2 ... Curcumine la plus biodisponible actuellement sur ... à des ingrédients approuvés par les règlements européens. ... présent dans la racine de curcuma ( Curcuma ...
(Date:11/26/2014)... 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con ... europeo in occasione di Hi Europe 2014 (dal 2 ... Si tratta della curcumina con la maggiore biodisponibilità ... cristalli) e ingredienti approvati dalle norme europee. ... della pianta curcumina ( Curcuma longa ) che è ...
(Date:11/24/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... today announced it has submitted an additional abbreviated new ... Administration (FDA), which brings the Company,s total number of ... now pending at the FDA. ... commented, "Our team here at IGI has continued to ...
(Date:11/24/2014)... Nov. 24, 2014  Last week, Representatives ... (D-NC) took a bold bipartisan step on ... the OPEN Act. Original co-sponsors of the legislation ... Act will incentivize drug makers and innovators to ... and pediatric cancers, which opens the door to ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... Expertise in Immunotherapy of CancerBETHESDA, Md., March 19 ... a biopharmaceutical company developing novel, proprietary antibodies for ... today announced the the appointment of Sir Walter ... advisory panel. Other members of the company,s advisory ...
... Based on its recent analysis of the device ... the 2009 North American Frost & Sullivan Company ... is one of the most lucrative in the ... has already experienced periods of breakthrough innovation as ...
... Baltic, Black and Mediterranean Seas, sampling water and ... Diego supporters Beyster Family Foundation Fund and matching ... 18, The J. Craig Venter Institute (JCVI) ... II Expedition--the J. Robert Beyster and Life Technologies ...
Cached Biology Technology:Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 2Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 3Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 4Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 5Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics 2Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics 3Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics 4Frost & Sullivan Recognizes ApaTech's Leadership in Orthopedic Biologics 5Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition 2Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition 3Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition 4Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition 5
(Date:11/6/2014)... cancer deaths occur because of metastasis, yet progress ... been slow. , "It,s been particularly challenging to ... Gujral, research fellow in systems biology at Harvard ... detected until after they,ve already metastasized." , Gujral ... that should help researchers better understand how metastasis ...
(Date:11/5/2014)... the UTSA College of Sciences, is one of ... a two-year $300,00 National Science Foundation (NSF) Early ... supports President Obama,s BRAIN Initiative, a federal effort ... will demystify complex brain processes. , According ... into the interactions of multiple components, each working ...
(Date:11/4/2014)... 2014 – University of Utah engineers developed the first ... fuel produce electricity without needing to ignite the fuel. ... portable electronics, off-grid power and sensors. , A study ... American Chemical Society journal ACS Catalysis . , ... reaction between a fuel and an oxygen-rich source such ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Jet-fueled electricity at room temperature 2
... Philadelphia, PA, April 11, 2013 A potential new ... for reducing alcohol consumption in alcohol dependent individuals, says ... Psychiatry . Traditionally, abstinence has been regarded as ... pharmacological treatments for alcoholism are approved only for relapse ...
... loss of limb control in individuals with spinal cord ... the neural pathways between brain and spinal cord, although ... remain functional. An artificial neural connection that bridges the ... potential to ameliorate the functional loss. Yukio Nishimura, ...
... including climate change, overfishing or loss of food supply ... collapse. Ecologists have long sought ways to measure the risk ... managers take steps to protect endangered populations. Last year, ... of collapse by monitoring how fast it recovers from small ...
Cached Biology News:A new treatment option for alcohol dependence: Reduced consumption rather than abstinence 2Early warning signs of population collapse 2Early warning signs of population collapse 3
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
... produces output at 470 nm; includes interface cable ... or installed into rack or desktop boxes ... is an LED that produces either pulsed or ... region -- for fluorescence measurements. The source is ...
... LNA microarray slides for microRNA expression ... incorporate Exiqons unique Locked Nucleic Acid (LNA) ... mismatch discrimination for short microRNA (miRNA) targets. ... 1 g total RNA (no need for ...
... Clear amber to slightly ... Contains 10 vials per set, each ... adjuvant homogenized in the following proportions ... Arlacel A (mannide monooleate emulsifier), and ...
Biology Products: